The mechanisms of action of CS on cartilage metabolism are not well understood.
Several in vitro studies demonstrated that CS has great influence on both cartilage explants and isolated articular chondrocytes. CS stimulates the proteoglycan synthesis of bovine and human chondrocytes [5, 6] , whereas it decreases interleukin-1ß (IL-1ß)-induced expression of matrix metalloproteinases-1, -3 and -13 and aggrecanases-1 and 2 [6] [7] [8] . Furthermore, some anti-inflammatory properties have been attributed to CS, based on its ability to inhibit human leukocyte chemotaxis and phagocytosis, to protect plasma membrane from oxygen reactive species [9] and to reduce cyclooxygenase-2 (COX-2) expression and prostaglandin E 2 production by chondrocytes [6, 10] . Recently, CS was also found to counteract IL-1ß-depressed expression of transforming growth factor-ß (TGF-ß) receptors in chondrocytes [6] .
However, it is unlikely that these limited chondroprotective and anti-inflammatory properties could be exerted in vivo by CS on articular cartilage following oral administration of the glycosaminoglycan. In fact, polysaccharides are poorly absorbed through the digestive system [11] , and only 12% to 13% of ingested CS is absorbed intact into the bloodstream [12] . Furthermore, the half-life of CS in the circulatory system is 3-15 min, after intravenous administration [12] . When CS was administered orally to patients as a single dose of 1200 mg/day, a time peak was observed at 4 h and a maximum plasma concentration of 3.8 ± 0.6 μg/ml was measured [9] . This level is below the concentrations of CS generally used in most of the published in vitro studies. All together, these data indicate that orally administered CS is not systematically distributed to articular cartilage and that the mechanism of CS effect in oral treatment of OA, if any, might be mediated by other pathways.
On the other hand, we may hypothesize that bringing CS in contact to joint cells could mimic the chondroprotective and anti-inflammatory effects of CS observed in vitro. This view has been recently reinforced by our study showing that CS was also capable of increasing the production of high-molecular-weight hyaluronan by cultured osteoarthritic synovial fibroblasts ( Fig. 1) [13] . Therefore, it is reasonable to suppose that CS injected into the synovial fluid would be in direct contact with both synoviocytes and superficial chondrocytes, and therefore would exert similar effects as those found in vitro. By providing a local source, one would also eliminate the need of large amounts of CS. As such, sufficient CS can be made available and not be lost via absorption into the bloodstream. In support of such approach, intra-articular delivery of CS has been recently shown to be effective for the repair of joint defects in a rabbit model [14] . Furthermore, it might be interesting to associate CS to the already existing HA intra-articular delivery. By combining these two glycosaminoglycans, which both have moderate anti-inflammatory properties [9, [15] [16] [17] , it may be possible to further improve therapeutic efficacy. Moreover, that CS could up-regulate the local hyaluronan synthesis by joint cells would probably provide the supply of hyaluronan for a longer period of time than single injection of exogenous hyaluronan, which is known to have a short-life period.
However, the problem of purity and chemical structure of commercial CS samples has to be solved first. Contrasting with hyaluronan, CS cannot be prepared by engineering, and animal extracts (bovine, ichthyc, avian) are still the only available sources. More information on the sequential arrangement of the disaccharide units within the chain is also required, since this may have an impact on the CS biological function. Today, the requirements for quality manufacturing of neutraceuticals are not as strict as for pharmaceuticals [18] [19] [20] [21] [22] [23] . Great differences have been found in the composition of commercial CS preparations, particularly in the ratio of 0-, 4-, and 6-sulfated disaccharides, reflecting the great differences in the species or tissue origin [22] .
In conclusion, to improve the efficacy of CS as a therapeutic agent in knee OA treatment, it would be of great interest to deliver solutions of this glycosaminoglycan directly into the synovial cavity, alone or in association with hyaluronan. This new approach will allow CS to exert its chondroprotective and anti-inflammatory effects on joint cells through the mechanisms already described in in vitro systems.
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